Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Withdrawn 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Genitourinary 1

Conditions

Neoplasms 4Neoplasm Metastasis 3Solid Tumors Harboring NTRK Fusion 1Precursor Cell Lymphoblastic Leukemia-Lymphoma 1Osteosarcoma 1Neuroblastoma 1Kidney Neoplasms 1Carcinoma, Renal Cell 1Breast Neoplasms, Male 1Breast Neoplasms 1

Interventions

pembrolizumab 11Nivolumab 7Sunitinib 6Cyclophosphamide 6aldesleukin 5Sorafenib 5Everolimus 5temsirolimus 4belzutifan 4atezolizumab 4Ipilimumab 4fludarabine 3cabozantinib 3Interferon-alpha 3Gene Expression Profiling 3Fluorouracil 3Docetaxel 3Cetuximab 3Busulfan 3valspodar 2sargramostim 2perifosine 2pazopanib 2ixabepilone 2entinostat 2ciforadenant 2belinostat 2Thiotepa 2Temozolomide 2Sirolimus 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 1 × Kidney Neoplasms × Suspensions × Clear all
NCT04260360 2020-08-04

Trial of NanoDoce Intratumoral Injection in Renal Cell Carcinoma

NanOlogy, LLC

Phase 1 Withdrawn
Genitourinary

Carcinoma, Renal Cell, Kidney Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡